The development pipeline is substantially shorter, if you can produce an mRNA vaccine you can theoretically produce any mRNA vaccine. Once you have the genetic sequence of the strain you're interested in, preparing one mRNA transcript is (more or less) the same as preparing any other. The same is not true for protein expression or live attenuated virus preparation. Preparing the vaccine at scale faster means getting to testing sooner, and testing sooner means results sooner.